Restricted accessResearch articleFirst published online 2021-09
How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics
Resistance to cancer chemotherapy is a major global health burden. Epidermal growth factor receptor (EGFR) is a proven therapeutic target for multiple cancers of epithelial origin. Despite its overexpression in >90% of head and neck squamous cell carcinoma (HNSCC) patients, tyrosine kinase inhibitors such as erlotinib have shown a modest response in clinical trials. Cellular heterogeneity is thought to play an important role in HNSCC therapeutic resistance. Genomic alterations alone cannot explain all resistance mechanisms at play in a heterogeneous system. It is thus important to understand the biochemical mechanisms associated with drug resistance to determine potential strategies to achieve clinical response. We investigated tyrosine kinase signaling networks in erlotinib-resistant cells using quantitative tyrosine phosphoproteomics approach. We observed altered phosphorylation of proteins involved in cell adhesion and motility in erlotinib-resistant cells. Bioinformatics analysis revealed enrichment of pathways related to regulation of the actin cytoskeleton, extracellular matrix (ECM)–receptor interaction, and endothelial migration. Of importance, enrichment of the focal adhesion kinase (PTK2) signaling pathway downstream of EGFR was also observed in erlotinib-resistant cells. To the best of our knowledge, we present the first report of tyrosine phosphoproteome profiling in erlotinib-resistant HNSCC, with an eye to inform new ways to achieve clinical response. Our findings suggest that common signaling networks are at play in driving resistance to EGFR-targeted therapies in HNSCC and other cancers. Most notably, our data suggest that the PTK2 pathway genes may potentially play a significant role in determining clinical response to erlotinib in HNSCC tumors.
Get full access to this article
View all access options for this article.
References
1.
AbeY, NaganoM, KugaT, et al. (2017). Deep phospho- and phosphotyrosine proteomics identified active kinases and phosphorylation networks in colorectal cancer cell lines resistant to cetuximab. Sci Rep, 7, 10463.
2.
AstsaturovI, RatushnyV, SukhanovaA, et al. (2010). Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal, 3, ra67.
3.
BasuD, BewleyAF, SperrySM, et al. (2013). EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. Mol Cancer Ther, 12, 2176–2186.
4.
Cancer Genome AtlasN. (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517, 576–582.
5.
CanelM, SecadesP, RodrigoJP, et al. (2006). Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res, 12,(11 Pt 1),3272–3279.
6.
CeramiE, GaoJ, DogrusozU, et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2, 401–404.
7.
ChafferCL, San JuanBP, LimE, and WeinbergRA (2016). EMT, cell plasticity and metastasis. Cancer Metastasis Rev, 35, 645–654.
8.
ChandrashekarDS, BashelB, BalasubramanyaSAH, et al. (2017). UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia, 19, 649–658.
9.
ChangX, IzumchenkoE, SolisLM, et al. (2013). The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS One, 8, e68966.
CheungHW, DuJ, BoehmJS, et al. (2011). Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov, 1, 608–625.
12.
CohenEE, HalpernAB, KaszaK, et al. (2009). Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol, 45, e155–e160.
13.
CooperJB, and CohenEE. (2009). Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck, 31, 1086–1094.
14.
DingL, LeyTJ, LarsonDE, et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 481, 506–510.
15.
EidS, TurkS, VolkamerA, RippmannF, and FulleS. (2017). KinMap: a web-based tool for interactive navigation through human kinome data. BMC Bioinformatics, 18, 16.
16.
FengR, and YangS. (2016). Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer. J Int Med Res, 44, 855–864.
17.
FortierAM, AsselinE, and CadrinM. (2013). Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J Biol Chem, 288, 11555–11571.
18.
FuY, ZhangY, LeiZ, et al. (2020). Abnormally activated OPN/integrin alphaVbeta3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol, 13, 169.
19.
FuchsBC, FujiiT, DorfmanJD, et al. (2008). Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res, 68, 2391–2399.
20.
GaoJ, AksoyBA, DogrusozU, et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 6, pl1.
21.
GilesKM, KalinowskiFC, CandyPA, et al. (2013). Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther, 12, 2541–2558.
22.
GolubovskayaVM. (2010). Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem, 10, 735–741.
23.
GusenbauerS, VlaicuP, and UllrichA. (2013). HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene, 32, 3846–3856.
24.
HoweGA, XiaoB, ZhaoH, et al. (2016). Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer. PLoS One, 11, e0150567.
25.
Huang daW, ShermanBT, and LempickiRA. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 37, 1–13.
26.
HuangL, and FuL. (2015). Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B, 5, 390–401.
27.
IchiharaE, WestoverD, MeadorCB, et al. (2017). SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res, 77, 2990–3000.
28.
JainAP, PatelK, PintoS, et al. (2019). MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. Sci Rep, 9, 18793.
29.
JuL, ZhouC, LiW, and YanL. (2010). Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem, 111, 1565–1574.
30.
JuniorWNW, WeberRS, LeeJJ, et al. (2011). Randomized trial of a short course of erlotinib 150 to 300mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: objective responses and clinical outcomes. J Clin Oncol 29(15_suppl),5520.
31.
KandaR, KawaharaA, WatariK, et al. (2013). Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling. Cancer Res, 73, 6243–6253.
32.
KanehisaM, GotoS, SatoY, FurumichiM, and TanabeM. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res, 40,(Database issue),D109–D114.
33.
KovacB, MakelaTP, and ValleniusT. (2018). Increased alpha-actinin-1 destabilizes E-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer. PLoS One, 13, e0196986.
34.
KrumbachR, SchulerJ, HofmannM, et al. (2011). Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer, 47, 1231–1243.
35.
LimY, HanI, JeonJ, et al. (2004). Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for Ras transformation of fibroblasts. J Biol Chem, 279, 29060–29065.
36.
Lo MuzioL, PannoneG, SantarelliA, et al. (2013). Is expression of p120ctn in oral squamous cell carcinomas a prognostic factor?. Oral Surg Oral Med Oral Pathol Oral Radiol, 115, 789–798.
37.
Madoz-GurpideJ, ZazoS, ChamizoC, et al. (2015). Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med, 13, 282.
38.
ManningG, WhyteDB, MartinezR, HunterT, and SudarsanamS. (2002). The protein kinase complement of the human genome. Science, 298, 1912–1934.
39.
MarinerDJ, DavisMA, and ReynoldsAB. (2004). EGFR signaling to p120-catenin through phosphorylation at Y228. J Cell Sci, 117,(Pt 8),1339–1350.
40.
McConkeyDJ, ChoiW, MarquisL, et al. (2009). Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev, 28, 335–344.
41.
McLeanGW, CarragherNO, AvizienyteE, et al. (2005). The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer, 5, 505–515.
42.
MitraSK, HansonDA, and SchlaepferDD. (2005). Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol, 6, 56–68.
43.
MrozEA, and RoccoJW. (2016). Intra-tumor heterogeneity in head and neck cancer and its clinical implications. World J Otorhinolaryngol Head Neck Surg, 2, 60–67.
44.
NavinN, KendallJ, TrogeJ, et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472, 90–94.
45.
NiehrF, EderT, PilzT, et al. (2018). Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection. Clin Cancer Res, 24, 158–168.
46.
NohataN, HanazawaT, KikkawaN, et al. (2011a). Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol, 38, 209–217.
47.
NohataN, SoneY, HanazawaT, et al. (2011b). miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget, 2, 29–42.
48.
OngSE, BlagoevB, KratchmarovaI, et al. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics, 1, 376–386.
49.
OrtizR, DiazJ, DiazN, et al. (2016). Extracellular matrix-specific Caveolin-1 phosphorylation on tyrosine 14 is linked to augmented melanoma metastasis but not tumorigenesis. Oncotarget, 7, 40571–40593.
50.
PintoSM, NirujogiRS, RojasPL, et al. (2015). Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics, 15, 532–544.
51.
RadhakrishnanA, NanjappaV, RajaR, et al. (2017). Corrigendum: a dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma. Sci Rep, 7, 46864.
52.
RajagopalanP, NanjappaV, PatelK, et al. (2018). Role of protein kinase N2 (PKN2) in cigarette smoke-mediated oncogenic transformation of oral cells. J Cell Commun Signal, 12, 709–721.
53.
RamonYCS, SeseM, CapdevilaC, et al. (2020). Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl), 98, 161–177.
54.
RappsilberJ, IshihamaY, and MannM. (2003). Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem, 75, 663–670.
55.
RaudvereU, KolbergL, KuzminI, et al. (2019). g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res, 47,(W1),W191–W198.
56.
RothenbergerNJ, and StabileLP. (2017). Hepatocyte growth factor/c-Met signaling in head and neck cancer and implications for treatment. Cancers (Basel), 9, 39.
57.
SatheG, PintoSM, SyedN, et al. (2016). Phosphotyrosine profiling of curcumin-induced signaling. Clin Proteomics, 13, 13.
58.
ShiQ, and BoettigerD. (2003). A novel mode for integrin-mediated signaling: tethering is required for phosphorylation of FAK Y397. Mol Biol Cell, 14, 4306–4315.
59.
ShibueT, and WeinbergRA. (2009). Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A, 106, 10290–10295.
60.
SiegDJ, HauckCR, IlicD, et al. (2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol, 2, 249–256.
61.
SolankiHS, RajaR, ZhavoronkovA, et al. (2018). Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. Oncoscience, 5, 21–38.
62.
SrikanthM, DasS, BernsEJ, et al. (2013). Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition. Neuro Oncol, 15, 319–329.
63.
StabileLP, HeG, LuiVW, et al. (2013). c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res, 19, 380–392.
64.
SuttonP, BorgiaJA, BonomiP, and PlateJM. (2013). Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer, 12, 76.
65.
SuzukiM, IshikawaH, TanakaA, and MatagaI. (2011). Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue. Hum Cell, 24, 21–29.
66.
SzklarczykD, GableAL, LyonD, et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 47,(D1),D607–D613.
67.
TausT, KocherT, PichlerP, et al. (2011). Universal and confident phosphorylation site localization using phosphoRS. J Proteome Res, 10, 5354–5362.
68.
TongX, TaninoR, SunR, et al. (2019). Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Respir Res, 20, 270.
69.
VizcainoJA, CoteRG, CsordasA, et al. (2013). The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res, 41,(Database issue),D1063–D1069.
70.
WilsonC, NicholesK, BustosD, et al. (2014). Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget, 5, 7328–7341.
71.
WuDW, ChenCY, ChuCL, and LeeH. (2016). Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Oncogene, 35, 621–630.
72.
YoshidaT, ZhangG, SmithMA, et al. (2014). Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res, 20, 4059–4074.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
